Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd.
  6. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD.

(4519)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
06/08/2021 06/09/2021 06/10/2021 06/11/2021 06/14/2021 Date
4225 4223 4267 4378 4435 Last
1443300 1903400 2587800 2592500 1154600 Volume
-0.07% -0.05% +1.04% +2.60% +1.30% Change
Financials
Sales 2021 829 B 7 528 M 7 528 M
Net income 2021 244 B 2 218 M 2 218 M
Net cash position 2021 451 B 4 098 M 4 098 M
P/E ratio 2021 30,0x
Yield 2021 1,38%
Sales 2022 828 B 7 522 M 7 522 M
Net income 2022 231 B 2 099 M 2 099 M
Net cash position 2022 546 B 4 957 M 4 957 M
P/E ratio 2022 31,7x
Yield 2022 1,42%
Capitalization 7 291 B 66 289 M 66 217 M
EV / Sales 2021 8,25x
EV / Sales 2022 8,14x
Nbr of Employees 7 555
Free-Float 37,7%
More Financials
Company
Chugai Pharmaceutical Co. Ltd specializes in the research, development, manufacturing and marketing of drugs especially for cancers (40.8% of net sales), bones and joints diseases treatment (18.4%), and kidney diseases (5.9%). Net sales are distributed geographically as follows: Japan (74,3%), Switzerland (22,8%) and other (2,9%). 
More about the company
Ratings of Chugai Pharmaceutical Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about CHUGAI PHARMACEUTICAL CO., LTD.
06/14Industrials Pull Back Amid Shift Away From Reopening Stocks -- Industrials Ro..
DJ
06/14CHUGAI PHARMACEUTICAL  : Files New Drug Application in Japan for Faricimab, the ..
AQ
06/14Toshiba chair blames ex-CEO for firm's woes
RE
06/14TOSHIBA  : chairman resists calls to resign, to bring in new directors
RE
06/14OSAMU NAGAYAMA : Proxy adviser ISS continues recommendation against appointing T..
RE
06/14Toshiba to Appoint New Directors to Reform Corporate Governance
DJ
06/13Toshiba changes board nominees as two step down in deepening crisis
RE
06/12Toshiba board to hold emergency meeting on Sunday, sources say
RE
06/12Toshiba board to hold emergency meeting on Sunday, sources say
RE
06/12TOSHIBA  : directors to hold emergency meeting on board reassignments, sources s..
RE
06/11CHUGAI PHARMACEUTICAL  : Files New Drug Application in Japan for Faricimab, the ..
PU
06/11Glass Lewis recommends against re-appointment of Toshiba board chairman, 4 ot..
RE
06/11PRESS RELEASE : Roche announces data at EHA2021 -2-
DJ
06/11PRESS RELEASE : New Roche data for Evrysdi show -2-
DJ
06/09Japanese shares rise, Eisai drops after 2 days of limit-up gains
RE
More news
News in other languages on CHUGAI PHARMACEUTICAL CO., LTD.
06/14OSAMU NAGAYAMA : Le président dit vouloir rester, propose un renouvellement du c..
05/31TOKYO STOCK EXCHANGE : Borsa Tokyo chiude in ribasso su prese di profitto, bene ..
04/26CHUGAI PHARMACEUTICAL  : CHMP empfiehlt EU-Zulassung von Enspryng (Satralizumab)..
04/22MÄRKTE ASIEN/Aktien erholen sich - Tokio weit vorn
04/21GlobeNewswire/Roche mit soliden Ergebnissen im -5-
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD.
More recommendations
Chart CHUGAI PHARMACEUTICAL CO., LTD.
Duration : Period :
Chugai Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Average target price 4 777,69 JPY
Last Close Price 4 435,00 JPY
Spread / Highest target 39,8%
Spread / Average Target 7,73%
Spread / Lowest Target -12,1%
EPS Revisions
Managers and Directors
NameTitle
Tatsuro Kosaka Chairman & Chief Executive Officer
Osamu Okuda President, COO & Representative Director
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
CHUGAI PHARMACEUTICAL CO., LTD.-19.41%66 289
JOHNSON & JOHNSON5.08%435 485
ROCHE HOLDING AG10.58%328 513
PFIZER, INC.7.66%221 837
NOVARTIS AG0.23%209 350
ELI LILLY AND COMPANY33.91%205 531